Johnson & Johnson’s Janssen unit will begin mid-stage trials of its COVID-19 vaccine in Spain on Monday, the program’s lead investigator said.
Alberto Borobia said 190 people would take part in the country’s trials, which will take place in three hospitals and be concluded by Sept. 22.
For more coronavirus news, visit our dedicated page.
The Spanish study is part of mid-stage, or Phase II, trials of the vaccine that are being carried out in three countries, also including the Netherlands and Germany.
The trials in the three countries will last two months and include 550 participants in total.
On Saturday, it was announced that British clinical trials for the AstraZeneca and Oxford University coronavirus vaccine have resumed after they were suspended this week following an illness in a study subject in Britain.